Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4070889 | 0.86 | TSHR (0.72) | TSHRCYP2D6ALDH1A1SMN1; SMN2KDM1A | |
| SCHEMBL3811219 | 0.85 | TSHR (0.76) | TSHRCYP2D6ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL347130 | 0.82 | TSHR (0.47) | TSHRCYP2D6ALDH1A1HPGDHSD17B10 | |
| SCHEMBL22307924 | 0.82 | — | — | |
| SCHEMBL20353639 | 0.81 | TSHR (0.61) | TSHRCYP2D6ALDH1A1HPGDHSD17B10 | |
| SCHEMBL10268129 | 0.79 | TSHR (0.63) | TSHRCYP2D6ALDH1A1HPGDKDM1A | |
| SCHEMBL19251154 | 0.77 | — | — | |
| SCHEMBL19490742 | 0.77 | TSHR (0.41) | TSHR | |
| SCHEMBL1509491 | 0.77 | TSHR (0.96) | TSHRCYP2D6ALDH1A1HPGDHSD17B10 | |
| SCHEMBL25653952 | 0.77 | GNAO1 (0.45) | TSHRCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151557-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-10-05 | — | — | US | disclosed |
| US-11760764-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230242544-A1 | QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-08-03 | — | — | US | disclosed |
| WO-2023129933-A2 | 6,6-FUSED HETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | 858 THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023088406-A1 | FUSED IMIDE DERIVATIVE | 正大天晴药业集团股份有限公司 | 2023-05-25 | — | — | WO | disclosed |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | Epizyme, Inc. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230052017-A1 | New compounds for treatment of diseases related to DUX4 expression | Facio Intellectual Property B.V. (NL) | 2023-02-16 | — | — | US | disclosed |
| US-20220395576-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-12-15 | — | — | US | disclosed |
| WO-2022253250-A1 | BRUTON'S TYROSINE KINASE DEGRADER CONTAINING FUSED-RING OR SPIRO-RING | 正大天晴药业集团股份有限公司 | 2022-12-08 | — | — | WO | disclosed |
| WO-2020252043-A1 | 5H-PYRROLO[3,2-d]PYRIMIDINE-2,4-DIAMINO COMPOUNDS AND ANTIBODY CONJUGATES THEREOF | SUTRO BIOPHARMA, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020252015-A1 | IMMUNOMODULATOR ANTIBODY DRUG CONJUGATES AND USES THEREOF | SUTRO BIOPHARMA, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020156323-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020037079-A1 | SUBSTITUTED INDOLES AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2020-02-20 | — | — | WO | disclosed |
| EP-3288931-B1 | CERTAIN PROTEIN KINASE INHIBITOR | CHONGQING FOCHON PHARMACEUTICAL CO LTD (CN) | 2019-11-06 | — | — | EP | disclosed |
| EP-3298017-B1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN LA ROCHE (CH) | 2019-08-14 | — | — | EP | disclosed |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| WO-2017120164-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Tabomedex Biosciences, LLC (US) | 2017-07-13 | — | — | WO | disclosed |
| US-20120010186-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, ERBB4 | TSHR 1374/4885CYP2D6 880/4885ALDH1A1 3822/4885 |
| US-20230242544-A1 | QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | KRAS, NRAS, HRAS | TSHR 4045/4885CYP2D6 1861/4885ALDH1A1 1817/4885 |
| US-11760764-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | TSHR 2323/4885CYP2D6 2611/4885ALDH1A1 301/4885 |
| US-20220395576-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | BCL6, BCL6B, BCL3 | TSHR 3100/4885CYP2D6 4179/4885ALDH1A1 3862/4885 |
| US-20120010186-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, FASN | TSHR 3261/4885CYP2D6 942/4885ALDH1A1 544/4885 |
| US-20230052017-A1 | New compounds for treatment of diseases related to DUX4 expression | SMN1; SMN2, UTRN, DDX21 | TSHR 4117/4885CYP2D6 4451/4885ALDH1A1 2332/4885 |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | EZH2, HDAC2, SETD2 | TSHR 2768/4885CYP2D6 4097/4885ALDH1A1 4808/4885 |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | TSHR 2621/4885CYP2D6 340/4885ALDH1A1 1339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.